Introduction: Current asthma guidelines recommend step-down of inhaled corticosteroids (ICS) to the minimum dose required for control of symptoms. Aim: To determine if supervised step-down of (ICS) in the community has any effect on asthmatic inflammation. Methods: 119 Community based asthmatics underwent progressive step-down of therapy until they became unstable or reached an (ICS) dose of 200 mg beclomethasone dipropionate (BDP) or equivalent. Once unstable, participants stepped back up to the last stable dose of ICS. Exhaled nitric oxide (NO) and mannitol challenge were performed at the start and end of step-down. Asthma Quality of Life Questionnaire (AQLQ) and spirometry were recorded at each step-down visit. Results: The median (interquartile range) BDP equivalent dose was significantly higher pre vs. post step-down: 400 mg (400e800) and 250 mg (200e400) per day respectively (P < 0.05). Examination of change in PD 10 in individual patients revealed that 34% had an improvement (>þ1 dd), 47% had no change (AEÀ1 dd), and 19% had a worsening (<À1 dd). The geometric mean fold ratio in NO for pre vs. post was 0.96 (95% CI 0.87 to 1.06, P Z 0.43). Mean (SEM) values for FEV 1 were 86.2% (1.51) vs. 84.5% (1.46) (P Z 0.04). There was a significant improvement in AQLQ.
Introduction
Inhaled corticosteroids (ICS) are the first line anti-inflammatory therapy in the treatment of asthma 1,2 however higher doses are associated with local and systemic adverse effects 3 Current asthma guidelines recommend stepping down of steroid dose once asthma control has been achieved. 1 There is a little evidence to suggest the best method to step-down treatment, or to ensure the safety of this approach. Hawkins and colleagues reduced the ICS dose in a range of asthmatic patients by a mean of 25% without a significant rise in asthma exacerbations or change in measures of health status. 4 They did not, however, examine surrogates of inflammation or airway hyperresponsiveness (AHR). It is recognised that symptoms correlate poorly with underlying inflammation. 5 Studies have demonstrated that titrating ICS to suppress surrogates of inflammation leads to reduced exacerbations and decreased airways remodelling. 6, 7 During the initial run-in phase of an ongoing community based clinical trial, ICS doses were stepped down to determine the lowest dose required to achieve stability. During this phase inflammatory surrogates including exhaled nitric oxide (NO) and AHR to mannitol were measured, in additional to lung function and quality of life. Mannitol was selected because it is portable and easy to use in a community setting. In addition, AHR to mannitol has been shown to be a good predictor of failure of ICS step-down. 8 Methods Participants 119 Eligible patients were recruited from 35 general practices throughout Tayside. This paper presents data obtained during the step-down phase of a large community based study. Participants were required to be aged 16 years and above, non smokers, have a diagnosis of persistent mild to moderate asthma, be clinically stable, and currently treated with !400 mg beclomethasone dipropionate (BDP) equivalent. At point of entry into the study, patients were required to demonstrate AHR to mannitol challenge in terms of a 10% fall in FEV 1 to a dose of mannitol of 635 mg or less. Exclusion criteria were: oral steroid in the preceding three months; aspirin intolerance; FEV 1 50% predicted; pregnancy; recurrent lower respiratory tract infections; and the presence of concomitant respiratory disease such as bronchiectasis. Patients who failed to become unstable on 200 mg BDP equivalent, or who were unable to step below 800 mg were withdrawn, as these were entry criteria for the subsequent study. The study was approved by the Tayside Committee on Medical Ethics (CTA, MF8000/13398), and all participants gave written informed consent.
Protocol
Patients underwent systematic step-down of their medication with two weekly follow-up. At screening, patients were issued with a peak expiratory flow (PEF) and symptom diary card and asked to monitor their PEF for two weeks: this served as their baseline for the study. Additional asthma therapies (leukotriene receptor antagonists (LTRAs) or theophyllines) were discontinued. Patients on combination inhalers were switched to an equivalent dose of inhaled steroid only. The dose of inhaled steroid was then halved every two weeks till patients were on 200 mg BDP equivalent or became clinically unstable (see Fig. 1 ). Clinical instability was defined as: diurnal variation in domiciliary PEF ! 20%; deterioration in FEV 1 ! 20% from baseline; mean use of inhaled reliever medication ! 0.5 puffs daily from baseline; an increase in symptom scores of !0.5 daily from baseline. (The asthma symptom score asks for a number analogue of symptoms from 0 to 3, where: 0 is symptom free; 1 is minimal symptoms; 2 is moderate symptoms which may limit activity; 3 severe symptoms which limit activity). Once unstable, participants stepped back up to the last stable dose of ICS (this was designated the 'lowest dose required for stability'). Exhaled NO and AHR were recorded at the start and end of the step-down, while asthma quality of life questionnaires and spirometry were measured throughout the step-down period.
Lung function
Lung function (FVC (forced vital capacity), FEV 1 (forced expiratory volume in 1 s)) was measured using a Micro Medical SuperSpiro (Micro Medical Ltd, Rochester, UK) spirometer according to the American Thoracic Society guidelines. 9 The highest of 3 values for FEV 1 , repeatable within 5%, was recorded and the percentage of percent predicted was calculated.
Mannitol challenge
Mannitol bronchial challenge was performed by administering mannitol gelatine capsules (Osmohaleä Pharmaxis Ltd, Sydney, Australia), inhaled from a dry powder device (Osmohaler, Pharmaxis Ltd. French's Forest, NSW, Australia) as previously described. 10 FEV 1 was measured 60 s after delivery of each dose (5, 10, 20, 40, 80, 160, 160, 160 mg) . The test continued until the FEV 1 had fallen 10% or the maximal cumulative dose of 635 mg had been administered. The provoking dose of mannitol to cause a 10% fall in FEV 1 (PD 10 ) was calculated by log linear interpolation.
Nitric oxide measurement
All participants underwent measurement of exhaled NO using a portable MINO (NIOX MINO Ò Airway Inflammation Monitor; Aerocrine AB, Solna, Sweden). Exhaled nitric oxide was measured during a sustained plateau of at least 8 s with a mouth flow rate of 50 ml/s and a pressure of 10 cm H 2 O following a tidal breath. The arithmetic mean was derived according to the current European Respiratory Society/ American Thoracic Society recommendations.
Mini juniper quality of life questionnaires (Mini-AQLQ)
At each study visit each patient completed the Juniper mini-AQLQ. 11 
Statistical analysis
SPSS version 15 (SPSS Inc, Chicago, Illinois) was used to perform the statistical analysis. Normality of data was assessed using the KolmogoroveSmirnov; non-Gaussian data were log transformed prior to analysis. Gaussian data were assessed using paired Student's t-tests. ICS dose pre and post step-down was analysed using Wilcoxon Signed Rank Tests. A probability value of less than 0.05 (two tailed) was considered significant.
Results

Demographics
One hundred and fifty patients entered the step-down phase of the clinical trial. One hundred and nineteen (49% female, 52% male) of these were randomised and entered the subsequent clinical trial. Thirty-one patients withdrew during the step-down phase: 1 failed to become unstable when cut back to 200 mg ICS; 2 became unstable on !800 mg ICS; 3 were unable to discontinue long acting beta agonist therapy; 2 were withdrawn due to failure to comply with the protocol; 6 withdrew due to personal reasons; and 17 Figure 1 Step-down procedure.
were lost to follow-up. The mean (SEM) age of participants who dropped out was 57 years (2) compared with 52 years (1) in those who completed step-down. Dropouts also had a significantly higher mannitol PD 10: 184.5 mg (95% CI 113.5e299.8) compared with 100 mg (95% CI 76.2e131.2), P Z 0.036. Other baseline characteristics did not differ significantly between the two groups ( Table 1) .
Withdrawal of medication
23 Participants were taking additional third line asthma therapy (long-acting b2-agonists (n Z 21), theophylines (n Z 1) or leukotriene receptor antagonists (n Z 1)) at the start of the step-down. Only four participants did not tolerate withdrawal of their third line therapy; one withdrew voluntarily. In patients who completed step-down, the median (interquartile range) dose of BDP or equivalent was 400 mg (400e800) at baseline, compared with 250 mg (200e400) post step-down, giving a median reduction of 150 mg (P < 0.0001) ( Fig. 2 ). Subjects underwent an average of 1.49 (0.07) step downs prior to either becoming unstable or reaching 200 mg BDP equivalent.
Surrogates of inflammation
The geometric mean (95% CI) mannitol PD 10 was 100.0 (76.2e131.2) at baseline; and 137.2 (104.5e180.1) post step-down. This represents a 0.46 doubling dose difference for pre vs. post step-down (95% CI 0.02e0.89), P Z 0.04. The geometric mean response-dose-ratio (%fall in FEV 1 / cumulative dose of mannitol given) was 1.73% fall/mg (1.71e1.75) at baseline and 1.95% fall/mg (1.93e1.96) post step-down, p Z 0.73. The geometric mean fold ratio for pre vs. post in exhaled NO was 0.96 (0.87e1.06), P Z 0.43.
Lung function
Mean (SEM) baseline spirometry values were: FEV 1 of 86.2% (1.5), FVC 91.6% (1.4), PEF 90.2% (1.7). FEV 1 post stepdown was 84.5% (1.5), P < 0.05. FVC and PEF showed no significant change post step-down (91.5% (1.4), and 90.0% (1.6), P Z 0.87).
AQLQ
The mean (SEM) AQLQ composite scores pre and post stepdown were 5.44 (0.10) vs. 5.83 (0.09) respectively, representing a mean improvement of 0.39 (95% CI 0.26 to 0.52), P < 0.001. Individual domains also showed statistically significant improvements (Tables 2 and 3 ).
Discussion
The present study demonstrates that supervised step-down of ICS in a community setting can be achieved without any worsening of airways inflammation, as measured by exhaled NO and mannitol challenge. This is in agreement with work carried out by Leuppi et al., who determined that the majority of patients could undergo a halving of their ICS dose without exacerbation. 8 We hypothesize that this may be due to improved adherence with supervised treatment during step-down. Whilst a significant reduction in ICS could also be achieved if patients had initially been over treated, there should have been a commensurate increase in airways inflammation on withdrawal of treatment, as has been reported elsewhere. 12 In the absence of such a change we feel that enhanced adherence is the logical conclusion. Adherence with asthma medications, particularly ICS, is known to be poor. 13 Patient-reported adherence rates are as low as 38%, 14, 15 and actual drug use is often even lower. Rand et al. compared patient-reported adherence to change in canister weight and demonstrated that although 73% of participants reported using their ICS three times daily, this was only confirmed in 15% by canister weight. 15 The commonest reasons to explain non-adherence include: patients' perception of their disease; such that they only take ICS when they become unwell as opposed to using it as 'preventer' therapy 14 ; and concerns over potential side effects. 13 There is evidence to suggest that regular disease monitoring addresses these issues and leads to benefits such as improved inhaler technique and adherence. 16, 17 In this regard, patients in the present study were reviewed fortnightly and may have additionally benefited from the positive reinforcement of regular spirometry, peak flow and symptom monitoring. Whilst this high level of supervision is too intensive to be reproduced in primary care, it suggests that the widespread practice of annual review may be too infrequent to adequately educate and support our asthmatic population.
Control of airways inflammation is of critical importance in asthma, as if left uncontrolled long-term it can lead to airway remodelling, even in asymptomatic patients. 18 Furthermore, studies in which asthma therapy was titrated to achieve suppression of surrogates of inflammation demonstrate that exacerbation rates can be reduced by up to five-fold, when compared with treatment guided by symptoms and lung function alone. 6, 7 To address this, the present study utilised bronchial challenge with mannitol and exhaled NO as suitable surrogates of asthmatic inflammation. Bronchial challenge tests are traditionally used to diagnose the presence of AHR, and to monitor response to treatment. 19 A.HR is a key feature of persistent asthma, which is considered to correlate well with underlying airways inflammation. 6 All participants in this study were required to exhibit AHR to mannitol as one of the inclusion criteria. Hence, we consider this makes an alternative diagnosis to asthma such as eosinophilic bronchitis unlikely. Nonetheless, we appreciate that AHR may vary over time, often increasing during exacerbations and Abbreviations: ICS, inhaled corticosteroids; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow rate; PD 10 , provocative dose of mannitol causing a 10% decrease in FEV 1 . Data presented as arithmetic mean (SEM) unless otherwise indicated. Baseline values are shown after washout before each randomised treatment period.
Step-down measurements were taken 2 weeks after reduction in steroid dose. a Expressed as median (interquartile range). b Shown as geometric mean (95% CI). c Expressed as percentage of that predicted by age, sex, and height, mean (SEM). 20 Mannitol challenge is a relatively novel indirect bronchial challenge test, which is known to be reproducible, and to correlate well with other surrogate markers of airways inflammation. 10, 21 Unlike other challenge tests, it is portable, simple, and quick to perform, and therefore ideally suited for use in primary care. Moreover, mannitol is an indirect stimulus, which induces AHR by osmotically stimulating inflammatory cells to release mediators which constrict airway smooth muscle. Fardon et al. showed that PD 10 correlates well with PD 15 , allowing an abbreviated challenge to be utilised without loss of sensitivity, whilst exposing the subject to less provocation agent. 22 The overall mean improvement observed in mannitol challenge (0.46 doubling dose shift in mannitol PD 10 ) was statistically significant, but would not be considered clinically significant. Examination of change in PD 10 in individual patients, as depicted in Fig. 3 , is more revealing than the magnitude of the overall mean shift for the group as a whole. A change in mannitol PD 10 of AEÀ1 doubling dose in a given patient is within the limits of intra-individual biological variability. Using these criteria we identified 34% of patients who had an improvement in PD 10 (i.e. a change >þ1 doubling dose), 47% who had no change (i.e. a change within AEÀ1 doubling dose), and 19% who had a worsening (i.e. change <À1 doubling dose) when comparing pre vs. post step-down ( Fig. 3) . In other words it was evident that the majority of patients (i.e. 81%) either had no change in AHR or improved. A minority of patients showed a worsening of AHR, which would be expected if subjects were initially adherent with treatment. A rate of 19% is consistent with adherence rates reported in previous studies. 15 A comparison of the baseline and post step-down characteristics of these three groups revealed no significant differences in terms of spirometry, NO or ICS dose, suggesting that in the majority of patients, airway inflammation was well controlled ( Table 4 ). Analysis of mannitol PD 10 showed that those who improved post step-down had significantly greater bronchial hyper-reactivity at baseline than the other two groups. Those who worsened post step-down had significantly more bronchial hyper-reactivity at the end of step-down. This correlates well with data obtained by Leuppi et al. who determined that developing AHR to mannitol during dose reduction was a good predictor of step-down failure. 8 Exhaled NO is an established surrogate of airways inflammation in asthma 23 and correlates closely to sputum eosinophil counts 24, 25 and mucosal eosinophilic markers. 26, 27 When used on its own as an inflammatory surrogate to titrate ICS, the results have been disappointing, 28 indeed, a recent Cochrane review has determined that exhaled nitric oxide cannot be recommended for tailoring the dose of inhaled corticosteroids in clinical practice. 29 However, its rapid response to changes in inflammatory status 30 and acute sensitivity to ICS makes it helpful when used in conjunction with other measures. It has been used as an early predictor of under-treatment (predicting exacerbation with FE NO and dose reduction). 12 In this regard our cohort showed no net change in NO during step-down. If the biological variability of NO is assumed to be <30% 31 : 64% of subjects demonstrated no significant increase in NO (Fig. 4) , These results correlate well with those of Leuppi et al. who found no significant increase in NO during dose reduction or exacerbation. We know from previous studies that 200 mg BDP is sufficient to suppress NO, even in the presence of persisting AHR, which may explain its lack of response in these circumstances. 20 However, when this observation is taken in conjunction with mannitol AHR, we believe it offers good evidence that airway inflammation was well controlled in this study, despite the relatively rapid rate at which ICS was reduced. Larger studies with a longer duration of follow-up are required to determine whether these improvements are maintained long-term.
Despite evidence to support the use of inflammatory markers in asthmatic assessment, current clinical practice dictates that ICS should be adjusted according to patientreported symptoms and spirometry. 1 In this respect, we observed a statistically significant improvement in quality of life scores, despite the reduction in ICS dose. There were no clinically significant changes in spirometry.
Treatment of asthmatic patients in primary care has been driven by results obtained from randomised controlled trials, during which treatment compliance is reinforced. These therefore, do not reflect a real life scenario. The current paper highlights the potential pit falls of extrapolating data to a primary care setting where compliance rates may be poor. Perhaps there is a need for the development of more effective strategies which support asthmatics to use established therapies correctly rather than continue a culture of escalating therapy, without frequent review and step-down if appropriate. Improvement of asthma care in the community may require an approach that includes more effective supervision and targeted assessment to enhance adherence and reduce airways inflammation.
In conclusion we have demonstrated that achieving a significant reduction in ICS dose is possible, without any deterioration in surrogate markers of inflammation in the majority of patients, and with an associated improvement in quality of life. This apparently disconnect between reduction in anti-inflammatory therapy and measured inflammation may reflect enhanced adherence through frequent supervision. Abbreviations: ICS, inhaled corticosteroids; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow rate; PD 10 , provocative dose of mannitol causing a 10% decrease in FEV 1 . Data presented as arithmetic mean (SEM) unless otherwise indicated. Baseline values are shown after washout before each randomised treatment period. Post step down measurements were made 2 weeks after the final dose reduction. a Significant difference (P < 0.01) between all three groups (except for pre step down dose between 'no change' and 'worsening').
Figure 4
Change in exhaled nitric oxide (i.e. post stepdownepre step-down) for each individual. The biological variability for nitric oxide lies within AE30%, so individuals lying within þ30% and À30% (depicted by interrupted line) can be assumed to show 'no change' in NO post step-down (43%). Individuals with >þ30% change can be assumed to show a rise in NO (worsening inflammation) (36%). Those with a <À30% change demonstrated a decrease in NO (improvement in inflammation) (21%).
